Eisai and Arena announced the launch of Belviq XR (lorcaserin HCl) extended-release tablets indicated for use with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) ≥30kg/m2 (obese) or BMI ≥27kg/m2 (overweight) with at least one weight-related medical condition (eg, hypertension, hypercholesterolemia, type 2 diabetes).

Belviq XR, a CIV controlled substance, was initially approved by the Food and Drug Administration (FDA) in July 2016. Lorcaserin HCl is a serotonin 2C receptor agonist that is presumed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus. 

Related Articles

Once-daily Belviq XR is available as 20mg extended-release tablets in 30-count bottles. Twice-daily Belviq is already available as 10mg tablets in 60-count bottles. 

For more information call (855) 235-8471 or visit BelviqXR.com.